Skip to main content
Features
Integrations
Data
Pricing
Log In
Start Free Trial
Features
Integrations
Data
Pricing
Log In
Start Free Trial
Jeannette Bannink
Sign up to set email alerts
35
Publications
159
Citation Statements Received
103
Citation Statements Given
How they've been cited
218
5
154
0
How they cite others
152
9
89
5
Affiliations
Aptevo Therapeutics (United states)
,
Emergent BioSolutions (United Kingdom)
Publications
Order By: Most citations
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Hernández‐Hoyos
1
,
Sewell
2
,
Bader
3
et al.
2016
Abstract
Show
73
1
41
0
Get access via publisher
Add to collection
Cite
Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor
Foy
1
,
Bannink
2
,
Sutherland
3
et al.
2001
Vaccine
55
2
36
0
Get access via publisher
Add to collection
Cite
Derivation and characterization of a highly pathogenic isolate of human immunodeficiency virus type 2 that causes rapid CD4
+
cell depletion in
Macaca nemestrina
McClure
1
,
Schmidt
2
,
Rey-Cuillé
3
et al.
2000
J of Medical Primatology
Abstract
Show
28
2
31
0
Get access via publisher
Add to collection
Cite
Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques
Comeau
1
,
Gottschalk
2
,
Daugherty
3
et al.
2019
Abstract
Show
12
0
12
0
Get access via publisher
Add to collection
Cite
Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study
Burge
1
,
Bookbinder
2
,
Kivitz
3
et al.
2008
Clinical Therapeutics
26
0
8
0
Get access via publisher
Add to collection
Cite
Abstract B111: Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primates
Comeau
1
,
Miller
2
,
Bannink
3
et al.
2018
Abstract
Show
4
0
7
0
Get access via publisher
Add to collection
Cite
Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques
Comeau
1
,
Gottschalk
2
,
Daugherty
3
et al.
2019
6
0
7
0
Get access via publisher
Add to collection
Cite
Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies
Comeau
1
,
Mitchell
2
,
Gottschalk
3
et al.
2017
Abstract
Show
3
0
5
0
Get access via publisher
Add to collection
Cite
1
2
3
4
